Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases

Sep 21, 2026

Uploaded by Aria

Numerous antibody biomarkers have been reported for cancer and atherosclerosis-related diseases. This study links atherosclerosis and diabetes mellitus with major outcomes including acute ischemic stroke, cardiovascular disease, and chronic kidney disease, and notes that cancer development often involves arterial disorders while DM increases cancer risk. Protein array screening identified KIAA0513 as an antigen recognized by serum IgG in atherosclerosis, with higher anti-KIAA0513 antibody levels measured by amplified luminescence proximity homogeneous assay-linked immunosorbent assay across multiple conditions. ROC analysis highlighted strongest performance for esophageal cancer, nephrosclerosis-type CKD, and DM.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Abstract

Antibody biomarker background

KIAA0513 antigen identification

Serum antibody validation across diseases

ROC performance and key clinical associations

MEDICINE INTERNATIONAL 4: 45, 2024 Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases TAKAKI HIWASA 1‑3 , YOICHI YOSHIDA 1 , MASAAKI KUBOTA 1 , SHU‑YANG LI 1,2,4 , BO‑SHI ZHANG 1,2 , TOMOO MATSUTANI 1 , SEIICHIRO MINE 1,5,6 , TOSHIO MACHIDA 1,6,7 , MASAAKI ITO8 , SATOSHI YAJIMA8 , MIKAKO SHIROUZU9 , SHIGEYUKI YOKOYAMA 10 , MIZUKI SATA 11,12 , KAZUMASA YAMAGISHI 11 , HIROYASU ISO 13 , NORIE SAWADA 14 , SHOICHIRO TSUGANE 14 , MINORU TAKEMOTO 15,16 , AIKO HAYASHI 15 , KOUTARO YOKOTE 15 , YOSHIO KOBAYASHI 17 , KAZUYUKI MATSUSHITA 18 , KOICHIRO TATSUMI 19 , HIROTAKA TAKIZAWA20 , GO TOMIYOSHI21 , HIDEAKI SHIMADA3,8 and YOSHINORI HIGUCHI 1 1 Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan; 2 3 Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143‑8541, Japan; 4Department of Rehabilitation in Traditional Chinese Medicine, The Second Affiliated Hospital of 5 Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China; Department of Neurological Surgery, Chiba Prefectural Sawara Hospital, Chiba 287‑0003, Japan; 6Department of Neurological Surgery, Chiba Cerebral and Cardiovascular Center, Chiba 290‑0512, Japan; 7Department of Neurosurgery, Eastern Chiba Medical Center, Chiba 283‑8686, Japan; 8Department of Gastroenterological Surgery and Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143‑8541, Japan; 9Laboratory for Protein Functional and Structural Biology, 10 RIKEN Center for Biosystems Dynamics Research, Yokohama, Kanagawa 230‑0045, Japan; RIKEN Structural Biology Laboratory, Yokohama, Kanagawa 230‑0045, Japan; 11Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Tsukuba 305‑8575, Japan; 12Department of Preventive Medicine and Public Health, Keio University School of Medicine, 13 Tokyo 160‑8582, Japan; Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan; 14Epidemiology and Prevention Group, Center for Public Health Sciences, 15 National Cancer Center, Tokyo 104‑0045, Japan; Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan; 16Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, Chiba 286‑8686, Japan; Department of Cardiovascular Medicine, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan; 17 18 Department of Laboratory Medicine & Division of Clinical Genetics, Chiba University Hospital, Chiba 260‑8677, Japan; 19Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan; 20 Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260‑0025, Japan; 21 Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama 340‑0203, Japan Received March 13, 2024; Accepted June 5, 2024 DOI: 10. 3892/mi.2024.169 Correspondence to: Dr Takaki Hiwasa, Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1‑8‑1, Chuo‑ku, Chiba 260‑8670, Japan E‑mail: hiwasa_takaki@faculty.chiba‑[u.jp](u.jp) Abbreviations: 95% CI, 95% confidence interval; AIS, acute ischemic stroke; AMI, acute myocardial infarction; AlphaLISA, amplified luminescence proximity homogeneous assay‑linked immunosorbent assay; Asympt‑CI, asymptomatic ischemic stroke; AUC, areas under the ROC curve; BC, breast cancer; BMI, body mass index; CAVI, cardio‑ankle vascular index; cCI, chronic‑phase cerebral infarction; CKD, chronic kidney disease; CRC, colorectal cancer; CRP, C‑reactive protein; CVD, cardiovascular disease; DM, diabetes mel

FAQs

What is the study’s main focus regarding KIAA0513 antibodies?

The study evaluates whether serum IgG antibodies against KIAA0513 can serve as a common biomarker shared by atherosclerosis-related diseases and cancers.

How was KIAA0513 initially identified in the patients?

Initial screening used the protein array method to identify KIAA0513 as an antigen recognized by serum IgG antibodies in patients with atherosclerosis.

Which conditions showed the highest ROC performance for anti-KIAA0513 antibodies?

The highest areas under the ROC curves were obtained for esophageal cancer, nephrosclerosis-type chronic kidney disease, and diabetes mellitus.

Sep 21, 2026

Uploaded by Aria